Sepio Capital 13F: Adds $162M to AbbVie (ABBV) Stake
Key Points
- Sepio Capital increased its AbbVie Inc. ABBV holdings by 475.7% during the quarter, bringing its total stake to 749,451 shares valued at roughly $196.0 million.
- AbbVie Inc. ABBV recently traded near $284.80, up about 49.3% from its 52-week low of $190.75.
- Several Wall Street firms recently updated their targets for the drug maker, while company insiders reported four stock transactions earlier in the year.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Sepio Capital boosted its position in AbbVie Inc. ABBV by 475.7% during the quarter, according to a Form 13F filed with the SEC on October 22, 2026. Disclosed in a filing on October 22, 2026, the fund added 619,274 shares to its previous holdings. The firm finished the quarter with 749,451 shares worth about $196.0 million.
ABBV
AbbVie Inc.
What Changed in Sepio Capital's AbbVie Position
Sepio Capital expanded its investment in the drug maker significantly during the period. The fund previously held 130,177 shares. With the addition of 619,274 shares, the stake grew by 475.7% to a final count of 749,451 shares valued at $196,048,988.
Other Institutional Activity in AbbVie
Other institutional investors adjusted their positions in the pharmaceutical company around the same time. Perigon Wealth Management trimmed its position by 15.9% during the quarter, ending with 93,671 shares worth about $24.5 million after shedding 17,805 shares.
AbbVie Inc. Stock Holds Steady
AbbVie closed at $285.19 on October 22, 2026, and recently traded around $284.80 as of October 23, 2026. The stock sits well above its 200-day moving average of $235.14 and trades close to its 52-week high of $291.40.
Recent Earnings
AbbVie generated $64.4 billion in trailing-twelve-month revenue with a net profit margin of 9.8%. The company reported trailing-twelve-month earnings of $3.54 per share. Its next quarterly earnings report is scheduled for October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie pays an annual dividend rate of $6.92 per share, giving it a dividend yield of 2.43%. The company's dividend payout ratio stands at 190.4%.
Insider Buying and Selling at AbbVie Inc.
Company insiders completed four transactions earlier in the year. General Counsel Perry C. Siatis sold 22,381 shares at $230.00 on February 25, 2026, for a total value of $5.1 million, and later sold 18,668 shares on March 2, 2026, worth about $4.4 million. Officer David Ryan Purdue sold 5,230 shares at $233.56 on March 4, 2026, totaling $1.2 million. Later, on August 14, 2026, officer Nicholas Donoghoe sold 32,710 shares at $250.00 for a total of $8.2 million.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the filing. JP Morgan maintained an Overweight rating with a $300.00 target on October 8, 2026. UBS maintained a Neutral rating with a $275.00 target on October 9, 2026. Guggenheim reiterated a Buy rating with a $288.00 target on October 9, 2026. RBC Capital reiterated an Outperform rating with a $280.00 target on October 13, 2026. Barclays maintained an Overweight rating and raised its target to $325.00 on October 21, 2026. Overall, the stock holds a consensus buy rating across 28 analyst opinions.
About AbbVie
AbbVie Inc. is a large biopharmaceutical enterprise based in North Chicago, Illinois. The company researches, develops, and sells a wide range of medical therapies and treatments across immunology, oncology, and other specialties. Key products include immunology treatments Skyrizi and Rinvoq, alongside oncology medications like Imbruvica and Venclexta.
Bottom Line
Sepio Capital's large addition reflects a growing institutional footprint for the biopharmaceutical firm. Investors will look toward the upcoming earnings release on October 30, 2026, for further updates on revenue and product growth.
Related Filing Alerts
Source: Sepio Capital's 13F filing on $ABBV (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts